PIPS Key Facts
Active Substance |
- Recombinant Neisseria meningitis group B Protein 936-741
- Meningococcal group W-135 oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
- Meningococcal group A oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
- Recombinant Neisseria meningitis group B Protein 287-953
- Recombinant Neisseria meningitis group B Protein 961c
- Meningococcal group Y oligosaccharides conjugated to Corynebacterium diptheriae CRM197 protein
- Outer Membrane Vesicles (OMV) from N. meningitidis Strain NZ 98/254
- Meningococcal group C oligosaccharides conjugated to Corynebacterium
diphtheriae CRM197 protein
|
Invented Name
|
Not available at present
|
PIP Number |
MHRA-100701-PIP01-22-M02 (update) |
Pharmaceutical form(s)
|
Pharmaceutical form(s):
- powder and suspension for suspension for injection
|
Therapeutic area
|
Therapeutic area:
|
Conditions / Indications
|
Conditions / Indications:
- Prevention of meningococcal meningitis
|
Route(s) of administration
|
Route(s) of administration:
|
PIP applicant
|
|
Decision Type
|
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
|
Compliance Check
|
|
Compliance Check Decision Date
|
|
Compliance Check Procedure Number
|
|